Lilly Turns Price Pressure Into Growth | Business and Finance News

Eli Lilly is turning GLP-1 drug pricing challenges into a growth engine, slashing net prices to boost volume and accessibility—driving 48% revenue and 33% EPS gains while expanding its market lead with top sellers like Zepbound and Mounjaro, plus next-gen oral options and pipeline drugs poised to dominate the future of weight-loss and diabetes treatment. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/4f9275f0a31036ca